Drug common name | LIFIRAFENIB |
INN | lifirafenib |
Description | Lifirafenib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target serine/threonine-protein kinase A-Raf, epidermal growth factor receptor, and serine/threonine-protein kinase B-raf. |
Classification | Small molecule |
Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1 |
PDB | — |
CAS-ID | 1446090-77-2 |
RxCUI | — |
ChEMBL ID | CHEMBL4209157 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 8762XZS5ZF (ChemIDplus, GSRS) |